Last reviewed · How we verify
Avenova
Avenova, developed by the University of Miami, is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Avenova |
|---|---|
| Also known as | Hypochlorous Acid |
| Sponsor | University of Miami |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine (PHASE4)
- Viral Conjunctivitis Treatment Study (NA)
- Ocular Comfort and Inflammation in Lid Hygiene Therapy (NA)
- Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) (PHASE4)
- AvenovaTM as a Sterile Skin Preparation Agent (EARLY_PHASE1)
- Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avenova CI brief — competitive landscape report
- Avenova updates RSS · CI watch RSS
- University of Miami portfolio CI